Comparing the current results to its competitors, Apellis Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 60.85 % year on year. The sales growth was above Apellis Pharmaceuticals Inc 's competitors' average revenue growth of 13.36 %, achieved in the same quarter.
Apellis Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, characterized by rapid technological advancements and a focus on proprietary products. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions. Notable competitors include AstraZeneca Pharmaceuticals LP, which markets eculizumab (Soliris) and ravulizumab (Ultomiris), and Novartis, which markets iptacopan. Other products such as danicopan and crovalimab have received FDA approval for related treatments. These competitors offer therapies targeting similar diseases and mechanisms of action, including complement inhibitors and other agents.
Due to outstanding performance in Overall company, revenue grew by 60.85 % Apellis Pharmaceuticals Inc improved its market share, to approximately 0.25 %.
June 6, 2025
Apellis Pharmaceuticals and Sobi Unveil Promising EMPAVELI Data Amid Revenue Challenges WALTHAM, Mass. and STOCKHOLM, June 6, 2025 In a significant breakthrough for the treatment of rare kidney diseases, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) have announced encouraging data from their ongoing Phase 3 VALIANT study. The findings were presented during a late-breaking session at the European Renal Association (ERA) Congress, highlighting the sustained efficacy of EMPAVELI (pegcetacoplan) in treating C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Promising Results in Kidney Disease Treatment These ...
October 16, 2024
Exploring Novel Therapeutic Frontiers: Apellis Pegcetacoplan Takes Centre Stage at ASN Kidney Week In a pivotal revelation for the nephrology community, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has unveiled its latest findings in the Phase 3 VALIANT study involving pegcetacoplan, targeting two formidable renal disorders: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). This development marks a significant stride in addressing the challenges posed by these rare and debilitating kidney diseases.The American Society of Nephrology (ASN) Kidney Week, recognised as one of the foremost congregations of nephrology experts worldwide, has accepted the VALIANT ...
September 20, 2024
Apellis Pharmaceuticals, Inc. has recently been in the spotlight following its pivotal updates concerning pegcetacoplan, an intravitreal injection developed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Following a convoluted journey marked by regulatory reviews and significant scientific presentations, Apellis faced both setbacks and renewed optimism within the European regulatory framework. This article synthesizes key information from two significant announcements by Apellis: the negative opinion received from the Committee for Medicinal Products for Human Use (CHMP) and the notable presentations planned at the Association for Research in Vision and Oph...
August 8, 2024
In a significant advancement for kidney disease treatments, Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Sobi) have jointly announced positive topline results from the Phase 3 VALIANT Study. This groundbreaking research focuses on the use of pegcetacoplan, a targeted therapy aimed at treating patients afflicted with two rare kidney disorders: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Both diseases are characterized by damaging inflammation of the kidneys, leading to potential kidney failure, and, notably, there are currently no approved treatment options available for affected patients.The VALIANT study marks a pivotal moment in n...
May 1, 2024
Apellis Pharmaceuticals, Inc. recently announced that they will be presenting 14 abstracts, including 11 oral presentations, at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The meeting, scheduled to take place from May 5th to May 9th in Seattle, will feature data that further supports the efficacy and safety profile of SYFOVRE (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).These presentations will provide valuable insights into the ongoing research and development efforts of Apellis Pharmaceuticals in the field of ophthalmology. The data presented will contribute to the growing body of evidence supporting t...
Publicly Traded Peers of Apellis Pharmaceuticals Inc
Annexon Inc Share Performance
-10.20%
This Quarter
Annexon Inc
Profile
Annexon Inc operates with a business model focused on developing therapeutic drugs to target and treat autoimmune and neurodegenerative disorders. The company conducts extensive research and preclinical studies to identify specific molecules that modulate the immune system and protect against neuroinflammation. Utilizing partnerships and collaborations, Annexon Inc aims to advance its drug candidates through clinical trials and potential commercialization to address unmet medical needs in the healthcare industry.
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Disc Medicine Inc is a biotechnology company that focuses on developing therapeutic treatments for hematologic diseases. Their business model revolves around leveraging their expertise in hepcidin biology to discover and develop small molecules that regulate iron metabolism. By targeting and modulating specific pathways, they aim to address unmet medical needs in conditions like iron overload disorders and anemia.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Sources:
Apellis Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Apellis Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
